BDBM485275 N-((1RS,3RS)-3-Acrylamidocyclopentyl)-4-oxo-5-(4- phenoxyphenyl)-4,5-dihydro-3H-1-thia-3,5,8-triazaacenaphthylene- 2-carboxamide::US10934310, Ex # 109::US10934310, Ex # 121::US11319329, Ex # 121::US12065446, Example 121

SMILES C=CC(=O)N[C@H]1CC[C@H](C1)NC(=O)c1sc2nccc3n(-c4ccc(Oc5ccccc5)cc4)c(=O)[nH]c1c23

InChI Key InChIKey=WJHBVLKPOCWSIK-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 485275   

TargetTyrosine-protein kinase BTK(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485275(US10934310, Ex # 121 | N-((1RS,3RS)-3-Acrylamidocy...)
Affinity DataIC50: 14.1nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485275(US10934310, Ex # 121 | N-((1RS,3RS)-3-Acrylamidocy...)
Affinity DataIC50: 269nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/12/2021
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485275(US10934310, Ex # 121 | N-((1RS,3RS)-3-Acrylamidocy...)
Affinity DataIC50: 14.1nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485275(US10934310, Ex # 121 | N-((1RS,3RS)-3-Acrylamidocy...)
Affinity DataIC50: 269nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485275(US10934310, Ex # 121 | N-((1RS,3RS)-3-Acrylamidocy...)
Affinity DataIC50: 14.1nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

TargetTyrosine-protein kinase BTK [389-659](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM485275(US10934310, Ex # 121 | N-((1RS,3RS)-3-Acrylamidocy...)
Affinity DataIC50: 269nMAssay Description:A BTK kinase lanthascreen binding assay monitors compound binding to unphosphorylated-BTK kinase domain (UP-BTK), by competing with a fluorescent lab...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent